Literature DB >> 19293958

Social functioning and quality of life as measures of effectiveness in the treatment of schizophrenia.

Jun Soo Kwon1, Jung-Seok Choi.   

Abstract

Entities:  

Year:  2009        PMID： 19293958      PMCID： PMC2652897          DOI： 10.1002/j.2051-5545.2009.tb00207.x

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  11 in total

1.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

Authors:  Sean R Tunis; Daniel B Stryer; Carolyn M Clancy
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

2.  Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning.

Authors:  Marco C G Merlo; Helene Hofer; Walter Gekle; Gregor Berger; Joseph Ventura; Ingrid Panhuber; Gabriela Latour; Stephen R Marder
Journal:  J Clin Psychiatry       Date:  2002-10       Impact factor: 4.384

3.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Authors:  Peter B Jones; Thomas R E Barnes; Linda Davies; Graham Dunn; Helen Lloyd; Karen P Hayhurst; Robin M Murray; Alison Markwick; Shôn W Lewis
Journal:  Arch Gen Psychiatry       Date:  2006-10

4.  Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.

Authors:  Stephen M Strakowski; Jacqueline L Johnson; Melissa P Delbello; Robert M Hamer; Alan I Green; Mauricio Tohen; Jeffrey A Lieberman; Ira Glick; Jayendra K Patel
Journal:  Schizophr Res       Date:  2005-10-15       Impact factor: 4.939

5.  Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.

Authors:  Michael Ritsner; Anatoly Gibel; Galina Perelroyzen; Rena Kurs; Mahmoud Jabarin; Yael Ratner
Journal:  J Clin Psychopharmacol       Date:  2004-12       Impact factor: 3.153

6.  Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

Authors:  J Kane; F Canas; M Kramer; L Ford; C Gassmann-Mayer; P Lim; M Eerdekens
Journal:  Schizophr Res       Date:  2006-11-07       Impact factor: 4.939

7.  Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.

Authors:  J Endicott; J Nee; W Harrison; R Blumenthal
Journal:  Psychopharmacol Bull       Date:  1993

8.  A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.

Authors:  Ann Mortimer; Stephen Martin; Henri Lôo; Joseph Peuskens
Journal:  Int Clin Psychopharmacol       Date:  2004-03       Impact factor: 1.659

9.  Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study.

Authors:  José Manuel Montes; Antonio Ciudad; Josep Gascón; Juan Carlos Gómez
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-06       Impact factor: 5.067

10.  Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.

Authors:  Robert Rosenheck; Deborah Perlick; Stephen Bingham; Wen Liu-Mares; Joseph Collins; Stuart Warren; Douglas Leslie; Edward Allan; E Cabrina Campbell; Stanley Caroff; June Corwin; Lori Davis; Richard Douyon; Lawrence Dunn; Denise Evans; Ede Frecska; John Grabowski; David Graeber; Lawrence Herz; Kong Kwon; William Lawson; Felicitas Mena; Javaid Sheikh; David Smelson; Valerie Smith-Gamble
Journal:  JAMA       Date:  2003-11-26       Impact factor: 56.272
View more
  8 in total

1.  Quality of life and social functioning of former long-stay psychiatric patients transferred into the community: a 10 year follow up study.

Authors:  S J McInerney; S Finnerty; E Walsh; L Spelman; N E Edgar; B Hallahan; C McDonald
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2018-04-28       Impact factor: 4.328

2.  Socio-demographic and clinical determinants of quality of life in Chinese patients with schizophrenia: a prospective study.

Authors:  Yu-Tao Xiang; Chuan-Yue Wang; Ying Wang; Helen F K Chiu; Jing-Ping Zhao; Qi Chen; Sandra S M Chan; Edwin H M Lee; Gabor S Ungvari
Journal:  Qual Life Res       Date:  2010-02-05       Impact factor: 4.147

3.  Is personal and social functioning associated with subjective quality of life in schizophrenia patients living in the community?

Authors:  Sofia Brissos; Vicent Balanzá-Martinez; Vasco Videira Dias; Ana Isabel Carita; Maria Luisa Figueira
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-03-08       Impact factor: 5.270

4.  Usefulness of EQ-5D for evaluation of health-related quality of life in young adults with first-episode psychosis.

Authors:  J Stochl; T Croudace; J Perez; M Birchwood; H Lester; M Marshall; T Amos; V Sharma; D Fowler; P B Jones
Journal:  Qual Life Res       Date:  2012-06-17       Impact factor: 4.147

5.  Quality of life after electroconvulsive therapy in persons with treatment resistant schizophrenia.

Authors:  Rohit Garg; B S Chavan; Priti Arun
Journal:  Indian J Med Res       Date:  2011-06       Impact factor: 2.375

6.  Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics.

Authors:  Andrea de Bartolomeis; Andrea Fagiolini; Marco Vaggi; Claudio Vampini
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-11       Impact factor: 2.570

7.  Mediation and moderation analyses: exploring the complex pathways between hope and quality of life among patients with schizophrenia.

Authors:  Wei-Liang Wang; Yu-Qiu Zhou; Nan-Nan Chai; Guo-Hua Li; Dong-Wei Liu
Journal:  BMC Psychiatry       Date:  2020-01-15       Impact factor: 3.630

8.  Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate.

Authors:  Pedro Such; José Manuel Olivares; Lizbeth Arias; Mette Troels Berg; Jessica Madera
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-10       Impact factor: 2.570
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.